edoc

Survival of Second-Line Biologics in Psoriasis: The British BADBIR Registry Data Informs Daily Practice

Navarini, Alexander A. and French, Lars E.. (2018) Survival of Second-Line Biologics in Psoriasis: The British BADBIR Registry Data Informs Daily Practice. The Journal of Investigative Dermatology, 138 (4). pp. 726-728.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/72198/

Downloads: Statistics Overview

Abstract

Psoriasis is one of the most chronic diseases in dermatology. Only a small percentage of patients ever experience relapse-free survival. The constant presence of plaques and comorbidities that affect the cardiovascular system, joints, and other organs greatly impair patients' quality of life. In addition, the life expectancy of psoriatic patients is shortened by several years. Hence, long-term and ideally systemic treatment with minimal adverse effects may be warranted.
Faculties and Departments:03 Faculty of Medicine > Bereich Spezialf├Ącher (Klinik) > Dermatologie USB > Dermatologie (Navarini)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Spezialf├Ącher (Klinik) > Dermatologie USB > Dermatologie (Navarini)
UniBasel Contributors:Navarini, Alexander
Item Type:Article, refereed
Article Subtype:Research Article
ISSN:1523-1747
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:05 Apr 2020 14:05
Deposited On:05 Apr 2020 14:05

Repository Staff Only: item control page